Quick Answer
ARROWHEAD PHARMACEUTICALS, INC. reported R&D Expense of $607.16 million for fiscal year 2025.
ARROWHEAD PHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $607.16M | +20.0% |
| 2024 | $505.87M | +43.2% |
| 2023 | $353.19M | +647.2% |
| 2015 | $47.27M | +104.3% |
| 2014 | $23.14M | +165.8% |
| 2013 | $8.71M | +61.5% |
| 2012 | $5.39M | +64.5% |
| 2011 | $3.28M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $177.20M | +29.3% | +29.3% |
| December 31, 2024 | $137.00M | — | +1729.0% |
| June 30, 2015 | $7.49M | +17.2% | -35.7% |
| March 31, 2015 | $11.64M | +123.2% | -34.4% |
| December 31, 2014 | $17.74M | +466.4% | +177.6% |
| June 30, 2014 | $6.39M | +263.9% | +22.5% |
| March 31, 2014 | $5.22M | +145.5% | +66.5% |
| December 31, 2013 | $3.13M | +98.7% | +78.4% |
- ARROWHEAD PHARMACEUTICALS, INC. showed an increase of +20.0% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2025 period, ARROWHEAD PHARMACEUTICALS, INC.’s r&d expense has grown by 18423.6% (from $3.28 million to $607.16 million).
- The most recent figure is from ARROWHEAD PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 25, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: